Ahre A, Björkholm M, Mellstedt H, Holm G, Brenning G, Engstedt L, Gahrton G, Hällen J, Johansson B, Johansson S G, Karnström L, Killander A, Lerner R, Lockner D, Lönnqvist B, Simonsson B, Stalfelt A M, Ternstedt B, Wadman B
Eur J Cancer Clin Oncol. 1983 Apr;19(4):499-506. doi: 10.1016/0277-5379(83)90113-x.
Patients with newly diagnosed multiple myeloma were randomly allotted to an intermittent high-dose melphalan/prednisone (MP) treatment (120 patients) or a continuous low-dose melphalan (M) regimen (99 patients). The median observation time was 59 months (range 33-84). Response to therapy was obtained in 45% of the MP group and 31% of the M group (P less than 0.05). No significant difference in response with regard to clinical stage was noted. Median survival was 36 months in the MP group and 29 months in the M group. Survival was longer in stage I and II myeloma than in the stage III cases, at least in the MP group. The median and 5-yr survival rates in stages I and II were significantly better in the MP than in the M group. Response to therapy was associated with length of survival, median survival being 62 months in responding patients and 20 months in non-responders. The MP and M groups did not differ in this respect.
新诊断的多发性骨髓瘤患者被随机分为间歇高剂量美法仑/泼尼松（MP）治疗组（120例患者）或持续低剂量美法仑（M）方案组（99例患者）。中位观察时间为59个月（范围33 - 84个月）。MP组45%的患者和M组31%的患者对治疗有反应（P<0.05）。未观察到临床分期对反应有显著差异。MP组的中位生存期为36个月，M组为29个月。至少在MP组中，I期和II期骨髓瘤患者的生存期长于III期患者。I期和II期患者的中位生存期和5年生存率在MP组显著优于M组。对治疗的反应与生存期相关，有反应的患者中位生存期为62个月，无反应者为20个月。MP组和M组在这方面无差异。
